Formulations and methods for vascular permeability-related diseases or conditions
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-043/42
A61K-031/44
출원번호
US-0726813
(2007-03-23)
등록번호
US-8222271
(2012-07-17)
발명자
/ 주소
Kleinman, David M.
Nivaggioli, Thierry
Gerritsen, Mary E.
Weber, David A.
출원인 / 주소
Santen Pharmaceutical Co., Ltd.
대리인 / 주소
Morrison & Foerster LLP
인용정보
피인용 횟수 :
1인용 특허 :
131
초록
Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.
대표청구항▼
1. A method to decrease vascular permeability in a subject in need thereof, comprising administering a therapeutic agent to the subject at a dose of no greater than an amount equivalent to 2 mg/kg of rapamycin, wherein the subject in need thereof has a disease or condition selected from the group co
1. A method to decrease vascular permeability in a subject in need thereof, comprising administering a therapeutic agent to the subject at a dose of no greater than an amount equivalent to 2 mg/kg of rapamycin, wherein the subject in need thereof has a disease or condition selected from the group consisting of retinal edema, neuroretinitis, vasculitis, toxic metabolic brain edema, hemangiomas, von Hippel Lindau disease, angioneurotic edema, snake bite, high altitude cerebral edema (HACE), high altitude pulmonary edema (HAPE), pulmonary edema associated with smoke inhalation, pulmonary edema associated with anoxia, hyponatremic brain edema, edema associated with blunt trauma, brain edema following stroke or closed head injury, and corneal edema,and the therapeutic agent is rapamycin or a pharmaceutically acceptable salt or ester thereof. 2. The method of claim 1, wherein the therapeutic agent is rapamycin, and the subject is a human subject. 3. The method of claim 1, wherein the therapeutic agent is rapamycin, and the subject in need thereof has a disease or condition is selected from the group consisting of retinal edema, von Hippel Lindau disease, and corneal edema. 4. The method of claim 1, wherein the therapeutic agent is administered to the subject in need thereof at a dose of no greater than an amount equivalent to 0.5 mg/kg of rapamycin. 5. The method of claim 1, wherein the therapeutic agent is administered to the subject in need thereof at a dose of no greater than an amount equivalent to 0.27 mg/kg of rapamycin. 6. The method of claim 1, wherein the therapeutic agent is administered to the subject in need thereof at a dose of no greater than an amount equivalent to 0.07 mg/kg of rapamycin. 7. The method of claim 1, wherein the therapeutic agent is administered to the subject in need thereof at a dose of no greater than an amount equivalent to 0.014 mg/kg of rapamycin. 8. The method of any of claims 4-7, wherein the therapeutic agent is rapamycin and the subject is a human subject. 9. The method of claim 1, wherein the therapeutic agent is rapamycin, and the rapamycin is administered in a formulation containing about 2% w/w rapamycin, about 4% w/w ethanol, and about 94% w/w PEG 400.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (131)
Zhang,Mingqiang; Sheridan,Rose Mary, 39-desmethoxyrapamycin, compositions and methods of use thereof.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Osbakken,Robert S.; Hale,Mary Anne; Leivo,Frederick T.; Munk,James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Peyman Gholam A. (New Orleans LA) Yang Dachuan (New Orleans LA) Khoobehi Bahram (New Orleans LA), Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same.
Goulet Mark (Westfield NJ) Beattie Thomas R. (Scotch Plains NJ) Wyvratt Matthew J. (Mountainside NJ), Fluoromacrolides having immunosuppressive activity.
Armistead David A. (Maynard) Boger Joshua S. (Concord) Meyers Harold V. (Lexington) Saunders Jeffrey O. (Littleton) Tung Roger D. (Cambridge MA), Immunosuppressive compounds.
Gregory, Susan A; Isakson, Peter C; Anderson, Gary, Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin.
Steiner Joseph P. (Hampstead MD) Snyder Solomon (Baltimore MD) Hamilton Gregory S. (Catonsville MD), Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth.
Wright,Carol; Llanos,Gerard H.; Rakos,Ronald; King,Kristin; Falotico,Robert, Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent.
Luly Jay R. (Libertyville IL) Kawai Megumi (Libertyville IL) Or Yat S. (Libertyville IL) Wiedeman Paul (Libertyville IL) Wagner Rolf (Gurnee IL), Macrocyclic immunomodulators.
Calne Roy (22 Arrow Road Cambridge GB2 CB22AS), Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Organ Helen M. (Fanwood NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity.
Robinson, Michael R.; Csaky, Karl G.; Yuan, Peng; Sung, Cynthia; Nussenblatt, Robert B.; Smith, Janine A., Ocular therapeutic agent delivery devices and methods for making and using such devices.
Gerhard Zenke DE; Hendrik Schuurman CH; Barbara Haeberlin CH; Armin Meinzer DE, Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin.
Smith ; III Amos B. (Merion PA) Condon Stephen M. (Philadelphia PA) Leazer ; Jr. Johnnie L. (Philadelphia PA) Maleczka Robert E. (Media PA) McCauley John A. (Philadelphia PA) Leahy James W. (San Lean, Processes and intermediates for preparing macrocycles.
Failli Amedeo A. (Princeton Junction NJ) Kao Wenling (Paoli PA) Steffan Robert J. (Langhorne PA) Vogel Robert L. (Stratford NJ), Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents.
Waranis Robert P. (Chazy NY) Harrison Maureen M. (St. Albans VT) Leonard Thomas W. (Plattsburgh NY) Enever Robin P. (Rouses Point NY), Rapamycin formulation for IV injection.
Harrison Maureen M. (St. Albans VT) Ofslager Christian L. (Plattsburgh NY) Waranis Robert P. (Chazy NY) Leonard Thomas W. (Wilmington NC), Rapamycin formulations for oral administration.
Weiner Alan L. (Cranbury NJ) Sinnett Kevin (Mukwonago WI) Johnson Sterling (Skillman NJ), Tack for intraocular drug delivery and method for inserting and removing same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.